Dyadic國際 DYAI 深 滬
等待開盤 04-30 09:30:00 美东时间
0.7577
-0.052
-6.47%
華盛通- 最 高0.85
- 今 開0.85
- 成交量 36.49万股
- 最 低 0.70
- 昨 收 0.8101
- 總市值 2760.96万
- 52周最高 1.346
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 0.6546
- 委 比 33.33%
- 總股本 3643.87万
- 歷史最高 10.98
- 量 比 8.26
- 振 幅 18.52%
- 歷史最低 0.6546
- 每 手 1
- 風險率 0.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyadic International Earnings Call Highlights Commercial Pivot
Dyadic International Inc. (($DYAI)) has held its Q4 earnings call. Read on for ...
03-29 08:01
Dyadic International shares are trading lower after the company reported worse-than-expected Q4 financial results.
Dyadic International shares are trading lower after the company reported worse-...
03-26 23:56
电话会总结 ｜ Dyadic(DYAI)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Dyadic业绩会实录，以下是2025年财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年总营收为310万美元，较2024年的350万美元下降40万美元，降幅11.4%。营收下降主要由于研发合作活动减少以及许可和里程碑收入降低，但部分被来自盖茨基金会和SACI的186万美元赠款收入增长所抵消。 **盈利能力：** 公司2025年运营亏损为720万美元，较2024年的590万美元扩大130万美元，亏损幅度增加22%。净亏损为740万美元（每股0.23美元），相比2024年净亏损580万美元（每股0.20美元），亏损同比增加27
03-26 12:03
Dyadic International Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $565.526K Miss $1.343M Estimate
Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 33.33 percent. This is a 20 percent decrease over losses of $(0.05) per share
03-26 04:22
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
Dyadic Applied BioSolutions signs OEM distribution agreement with IBT Bioservices
Dyadic Applied BioSolutions signs OEM distribution agreement with IBT Bioservices Dyadic Applied BioSolutions entered an OEM distribution agreement with IBT Bioservices to commercialize Dyadic-produced recombinant protein products through IBT’s sales channels. The initial products expected under the
03-16 19:20
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic Applied BioSolutions (NASDAQ: DYAI) has entered into an OEM distribution agreement with IBT Bioservices, a life sciences reagent manufacturer. This collaboration allows Dyadic to commercialize its recombinant protein products, including DNase I and transferrin, through IBT's established sales channels, expanding market access and supporting Dyadic's revenue goals. The partnership reflects Dyadic's strategy to diversify its commercializatio...
03-16 11:20
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic International, a global biotech company, announced it will report its 2025 financial results and host a conference call on March 25, 2026, at 5:00 p.m. ET. The call will include a corporate update and Q&A session accessible via dial-in or webcast. Dyadic produces high-value proteins using proprietary platforms for life sciences, food, and industrial applications.
03-11 20:10
Dyadic International Establishes At-the-Market Equity Offering Program
Dyadic International ( ($DYAI) ) has shared an announcement. On March 6, 2026, ...
03-07 06:31
Dyadic Applied BioSolutions And Inzymes Announced Planned 2026 Commercialization Of Recombinant Non-animal Bovine Chymosin, Key Enzyme Used In Cheese Production And Dairy Processing
Completion of these development activities represents a contractual milestone under the parties' 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic's proprietary
03-02 20:24
